Gamma radiation-induced grafting of poly(butyl acrylate) onto ethylene vinyl acetate copolymer for improved crude oil flowability.

Ethylene vinyl acetate (EVA) copolymers are widely employed as pour point depressants to enhance the flow properties of crude oil. However, EVA copolymers have limitations that necessitate their development. This work investigated the modification of EVA via gamma radiation-induced grafting of butyl acrylate (BuA) monomers and the evaluation of grafted EVA as a pour point depressant for crude oil. The successful grafting of poly(butyl acrylate) p(BuA) onto EVA was verified through grafting parameters, FTIR spectroscopy, and 1H NMR spectroscopy. Treating crude oil with 3000 ppm of (EVA)0kGy, (EVA)50kGy, and (1EVA:3BuA)50kGy yielded substantial reductions in pour point of 24, 21, and 21 °C, respectively. Also, rheological characterization demonstrated improving evidenced by a viscosity reduction of 76.20%, 67.70%, and 71.94% at 25 °C, and 83.16%, 74.98%, and 81.53% at 12 °C. At low dosages of 1000 ppm, the EVA-g-p(BuA) exhibited superior pour point reductions compared to unmodified EVA, highlighting the benefit of incorporating p(BuA) side chains. The grafted EVA copolymers with p(BuA) side chains showed excellent potential as crude oil flow improvers by promoting more effective adsorption and co-crystallization with paraffin wax molecules.

2-Thioxo-3,4-dihydropyrimidine and thiourea endowed with sulfonamide moieties as dual EGFRT790M and VEGFR-2 inhibitors: Design, synthesis, docking, and anticancer evaluations.

The effectiveness of a new series of thiopyrimidine and thiourea containing sulfonamides moieties was tested on HCT-116, MCF-7, HepG2, and A549. HepG2 cell line was the one that all the new derivatives affected the most. The greatest potent compounds against the four HepG2, HCT116, MCF-7, and A549 cell lines were 8f and 8g with IC50 = 4.13, 6.64, 5.74, 6.85 µM and 4.09, 4.36, 4.22, 7.25 µM correspondingly. Compound 8g exhibited higher activity than sorafenib against HCT116 and MCF-7 but exhibited lower activity against HepG2 and A549. Moreover, compounds 8f and 8g exhibited higher activities than erlotinib on HepG2, HCT116, and MCF-7 but demonstrated lower activity on A549. The most potent cytotoxic derivatives 6f, 6g, 8c, 8d, 8e, 8f, and 8g were examined on normal VERO cell lines. Our derivatives have low toxicity on VERO cells with IC50 values ranging from 32.05 to 53.15 µM. Additionally, all compounds were assessed for dual VEGFR-2 and EGFRT790M inhibition effects. Compounds 8f and 8g were the most potent derivatives inhibited VEGFR-2 at IC50 value of 0.88 and 0.90 µM, correspondingly. As well, derivatives 8f and 8g could inhibit EGFRT790M demonstrating strongest effects with IC50 = 0.32 and 0.33 µM sequentially. Additionally, the greatest active derivatives ADMET profile was evaluated in relationship with sorafenib and erlotinib as reference agents. The data attained from docking were greatly related to that achieved from the biological testing.